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AnnArbor, Michigan, JOHN R. GRAYBILL, M.D., SanAntonio, Texas, DAVID A. STEVENS, M.D., 
JOHNS. HOSTETLER, M.D., San Jose, California, GRETCHEN CLOUD, M.s., 
WILLIAM E. DISMUKES, M.D., Birmingham, Alabama, 
and Other Members of the NIAID Mycoses Study Group* 
PURPOSE: To describe the clinical presentation 
and outcomes of treatment with itraconazole in 
patients with sporotrichosis. 
METHODS: A culture for Sporothrix s&en&i 
or compatible histopathology was required for 
inclusion in the study. Patients with both cuta- 
neous and systemic sporotrichosis were treated. 
Patients received from 100 to 600 mg of itracona- 
zole daily for 3 to 18 months. Patients were clas- 
sified as responders or nonresponders. Respond- 
ers were further classified as remaining on 
treatment, relapsed, or free of disease. Nonre- 
sponders included patients who failed to respond 
or progressed during treatment with 
itraconazole. 
RESULTS: Twenty-seven patients (mean age: 53 
years) were treated with 30 courses of itracona- 
zole. Diabetes mellitus and alcoholism were pre- 
sent in eight and seven patients, respectively. 
Sites of involvement included lymphocutaneous 
alone in 9 patients, articular/osseous in 15 (mul- 
tifocal in 3), and lung in 3. Prior therapy was 
unsuccessful in 11 patients. Among the 30 
courses, there were 25 responders and 5 nonre- 
sponders. All 5 nonresponders received at least 
200 mg daily of itraconazole for durations that 
ranged from 6 to 18 months. Of the 25 respond- 
ers, 7 relapsed 1 to 7 months after treatment du- 
rations of 6 to 18 months. Of the 7 who relapsed, 
2 are responding to a second course. One re- 
sponder was lost to follow-up after 10 months of 
*See appendix. 
From the Audie L. Murphy Memorial Veterans Hospital and University 
of Texas Health Science Center (PKS-M, JRG), San Antonio, Texas: the 
Department of Veterans Affairs Medical Center and University of Michi- 
gan Medical School (CAK), Ann Arbor, Michigan: the Santa Clara Valley 
Medical Center and Stanford University Medical School (DAS, JSH), San 
Jose, California: University of Alabama at Birmingham (GC, WED), Bir- 
mingham, Alabama, and the National Institute of Allergy and infectious 
Diseases (members of the NIAID Mycoses Study Group), Bethesda, 
Maryland. 
This work was supported in part by the National Institute of Allergy and 
Infectious Diseases Mycoses Study Group (Grant NOI-AI-52562) and 
Janssen Research Foundation. 
Requests for reprints should be addressed to Patricia Kay Sharkey- 
Mathis, M.D., Department of Medicine, Division of Infectious Diseases, 
University of Texas Health Science Center, 7703 Floyd Curl Drive, San 
Antonio, Texas 78284-7881. 
Manuscript submitted September 17, 1992, and accepted in revised 
form January 15. 1993. 
treatment with itraconazole. Of the remaining 
17 responders, 3 remain on treatment, and 14 are 
free of disease over follow-up durations of 6 to 
42 months (mean: 17.6 months). Itraconazole was 
well tolerated with few side effects noted. 
CONCLUSIONS: These results document the effi- 
cacy of itraconazole in the treatment of cutane- 
ous and systemic sporotrichosis. 
S porotrichosis is a mycotic infection caused by the dimorphic fungus Sporothrix schenckii. 
The organism exists saprophytically in nature 
worldwide [l-7]. The spectrum of disease has been 
classified into two major categories: systemic and 
cutaneous inoculation sporotrichosis, with the lat- 
ter considered far more common [l-6,8]. Involve- 
ment in systemic sporotrichosis may be multifocal 
or unifocal, typically with cutaneous, pulmonary, 
articular, osseous, genitourinary, or central nervous 
system foci [l-3]. Opportunistic infections may ac- 
count for the increasing frequency of systemic spo- 
rotrichosis [2,7,8]. The poorer prognosis with multi- 
focal systemic disease is probably due to the more 
severe underlying immunosuppression in these pa- 
tients [2]. More common than multifocal disease, 
unifocal systemic sporotrichosis often has a chronic, 
progressive course [4,8]. A pulmonary portal of en- 
try, with hematogenous dissemination to other or- 
gans, has been proposed in the pathogenesis of sys- 
temic sporotrichosis [l-6,8,9]. However, cutaneous 
inoculation can also lead to involvement of underly- 
ing tendons and joints, and can rarely disseminate 
[l-3,6,7]. 
Therapy of sporotrichosis is primarily pharmaco- 
logic, but surgical intervention can play an impor- 
tant role, with resection occasionally being curative 
[4,5,10]. Spontaneous remissions of both cutaneous 
and pulmonary infections have rarely been report- 
ed [ll-131. However, due to the associated morbid- 
ity and rarely mortality, treatment is recommended 
for active infection [5,8]. In addition to difficulties 
with tolerance, toxicity, and administration, cur- 
rent regimens, including amphotericin B, ketocona- 
zole, or a saturated solution of potassium iodide 
@SKI), are of limited efficacy in more recalcitrant 
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systemic sporotrichosis. Therapeutic options of 
equal or greater efficacy are needed. 
Clinical experience with the new oral triazole 
antifungal itraconazole continues to accumulate in 
the United States and worldwide. It has been used 
investigationally for several years in a variety of 
mycoses, with numerous reports supporting its 
safety and efficacy. Gastrointestinal and endocrine 
toxicities appear to be less frequent for itraconazole 
than for ketoconazole [14-161. In uitro, itraconazole 
is active against S. s&en&ii, and animal models 
support its efficacy in the treatment of experimen- 
tal sporotrichosis [14,17,18]. Relatively few reports 
have been published using itraconazole to treat spo- 
rotrichosis in humans, but these suggest therapeu- 
tic efficacy [6,14,18,20,22]. The highly lipophilic 
character with accumulation in the skin and its slow 
clearance make itraconazole an ideal agent for the 
treatment of sporotrichosis [14,17]. This report re- 
views our experience with itraconazole in the treat- 
ment of cutaneous inoculation and systemic 
sporotrichosis. 
PATIENTS AND METHODS 
Patients were treated either as part of a National 
Institute of Allergy and Infectious Diseases Myco- 
ses Study Group open trial of itraconazole for en- 
demic mycoses or on a compassionate treatment 
protocol made possible by Janssen Research Foun- 
dation. Patients were treated at 11 different institu- 
tions from 1984 to 1991. All patients gave informed 
consent for treatment with itraconazole. Two pa- 
tients in the current series were reported previous- 
ly, but additional follow-up is included in this re- 
port [6,15]. 
Entry Criteria 
Patients with both cutaneous inoculation and 
systemic sporotrichosis were included. A culture 
positive for S. schenckii or histopathology compati- 
ble with this infection was required for inclusion in 
the study. If the patient had relapsed after prior 
therapy, a positive culture or clinical evidence of 
relapse was required. 
Treatment Regimens 
The dose of itraconazole ranged from 100 to 600 
mg daily. Lower doses of itraconazole were used 
during early periods of this study, whereas doses of 
400 mg daily were commonly used during later peri- 
ods; only one patient received 600 mg daily. Dose 
escalation was allowed if the response was deter- 
mined to be suboptimal. Patients were recommend- 
ed to take their dose with food. Patients were eva- 
luable if they had received at least a 3-month 
duration of itraconazole. One patient, who was lost 
to follow-up with active disease, was excluded from 
analysis based on this 3-month criterion. Concur- 
rent therapy with other antifungal or immunologic 
agents was not allowed. Patients were not allowed 
to take concomitant antacids or Hs blockers be- 
cause of the possibility of impaired absorption of 
itraconazole. Serum levels for itraconazole were not 
measured routinely. Pill counts to assess compli- 
ance were not performed. 
Response to Therapy 
Based on the investigators’ assessment of out- 
come to treatment with itraconazole, patients were 
classified as responders or nonresponders. Re- 
sponders were further classified as remaining on 
treatment, relapsed, free of disease, or lost to fol- 
low-up. Responders remaining on treatment were 
determined by investigators to have evidence of im- 
provement. Relapse was determined by the devel- 
opment of new or recurrent lesions after itracona- 
zole was discontinued. Nonresponders included 
those patients who failed to respond or progressed 
during treatment with itraconazole. Both nonre- 
sponders and responders who relapsed were consid- 
ered treatment failures. However, responders who 
relapsed could receive a second course of itracona- 




Twenty-seven patients with sporotrichosis were 
treated with 30 courses of itraconazole. Demo- 
graphic features and risk factors are presented in 
Table I for the overall patient cohort and for each 
of the four disease categories (lymphocutaneous, 
systemic unifocal pulmonary, systemic unifocal ar- 
titular/osseous, and systemic multifocal sporotri- 
chosis). Twenty-one patients were white, and two 
each were black, Native American, and Hispanic. 
Of the six nonwhite patients, five had systemic in- 
volvement. There were 22 men and 5 women, with a 
mean age of 53 years and a range of 22 to 86 years. 
Alcoholism and diabetes mellitus were common un- 
derlying illnesses, present in seven and eight pa- 
tients, respectively. One patient with pulmonary 
sporotrichosis had underlying chronic obstructive 
pulmonary disease (COPD). Of the 16 patients with 
underlying illnesses, 14 had systemic involvement. 
No patient had severe immunosuppression. Four 
patients had hobbies or occupations that placed 
them at risk for acquiring sporotrichosis. One of 
these patients acquired lymphocutaneous disease 
following inoculation from a laboratory accident. 
Another patient with lymphocutaneous involve- 
ment was a Christmas tree farmer. One patient, 
with pulmonary involvement, operated heavy con- 
struction equipment in landscaping and earthmov- 
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TABLE I 
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ing. The fourth patient, with articular/osseous in- course of itraconazole. Histopathology was compat- 
volvement, was a rose gardener. ible with sporotrichosis in 11 patients. 
Sites of Involvement Symptoms and Signs 
Sites of involvement included lymphocutaneous 
in 9 patients, articular/osseous in 15 (3 with multi- 
focal), and lung in 3 (unifocal). Seven of nine pa- 
tients with lymphocutaneous disease had skin le- 
sions only, and two had skin lesions and lymph node 
involvement. Eleven of 15 patients with articu- 
lar/osseous sporotrichosis had arthritis, with or 
without contiguous bone involvement, 2 had teno- 
synovitis, and 2 had osseous sporotrichosis without 
joint involvement. Twelve patients had unifocal ar- 
titular/osseous involvement. Of the three patients 
with systemic multifocal sporotrichosis, two had 
two joints involved, and one had a single joint in- 
volved and a distant cutaneous lesion. The knee, in 
seven patients, was the most common joint in- 
volved, followed by the wrist and elbow in four and 
three patients, respectively. Excluding the two pa- 
tients with more than one joint involved, the right 
side was involved in all five patients with upper 
extremity disease. Central nervous system involve- 
ment was not observed. 
The only constitutional symptom reported was 
weight loss in one patient with pulmonary sporotri- 
chosis. Fever was not reported. Patients with lym- 
phocutaneous involvement typically had the skin 
lesion and/or lymphadenopathy as the only symp- 
tom and sign reported. Erythema was described in 
two patients, pain and ulceration in one patient, 
and drainage in one patient with lymphocutaneous 
sporotrichosis. One patient with articular involve- 
ment had no symptoms or signs recorded, but all 
other patients with articular/osseous sporotrichosis 
had pain and swelling of the affected joint. Cutane- 
ous drainage was described in four patients, de- 
creased range of motion in three patients, and in- 
creased warmth over the affected area in three 
patients with articular/osseous sporotrichosis. All 
three patients with pulmonary sporotrichosis had 
cough and sputum production. Hemoptysis was 
noted in two patients, and chest pain in one patient 
with pulmonary sporotrichosis. 
All but one patient had a positive culture for S. 
s&en&ii at the time that treatment with itracona- 
zole commenced. However, this patient had a posi- 
tive culture 2 months into treatment with itracona- 
zole. One patient, relapsing after his initial course of 
itraconazole, had a positive culture prior to a course 
of fluconazole during which disease progressed, but 
the culture was not repeated prior to the second 
Prior Therapy 
Eleven patients had received prior unsuccessful 
therapy for sporotrichosis. The manner in which 
prior therapy was recorded varied among investiga- 
tors. Some patients received more than one agent. 
Therapy with SSKI was attempted in four patients, 
three with lymphocutaneous and one with articu- 
lar/osseous involvement. SSKI was discontinued in 
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TABLE II 
Outcome of Treatment With ltraconazole in 30 Episodes of 
Sporotrichosis in 27 Patients 
IT2 Dose ITZ Duration 
Type of No. of 
Response Courses Mean (mg’daange Mean(mO)R 
Nonresponder 5 380 200-600 12.6 6-18 
Responder 25 
Remain on ITZ 
Y 
367 300-400 10.5t 6-18 
Relapsed 333 200-400 7.4 5-18 
Lost to F/U 1 400 N/A 10 N/A 
Free of disease 14 250 100-400 7.8 3-15 
2 = itraconazole; F/U = follow-up; N/A = not applicable, 
one patient because of toxicity after 5 days, and in 
three for failure after 12 days, 3 months, and 5 
months, respectively. Four patients with articu- 
lar/osseous sporotrichosis and one with pulmonary 
involvement received therapy with amphotericin B, 
at total doses of 1.5 to 2.5 g (mean: 2.0 g); one failed 
to respond and the other four relapsed after therapy 
was stopped. Therapy with ketoconazole failed in 
six patients, and with fluconazole in two others. 
Two of the six patients received less than 1 month 
of treatment with ketoconazole at 400 mg/d. Total 
doses of 24 and 36 g of ketoconazole were recorded 
in two other patients. Another patient failed sepa- 
rate courses of 7 and 9 months’ duration at 400 mg 
daily of ketoconazole. The other patient in whom 
ketoconazole failed received more than 4 years of 
therapy with doses up to 600 mg daily. 
Response to ltraconazole Therapy 
Itraconazole therapy was given at doses of 100 to 
600 mg daily over durations that ranged from 3 to 18 
months, with three patients continuing on treat- 
ment. Most patients received 200 or 400 mg daily. 
Three patients received a second course of therapy 
with itraconazole and are counted twice in the anal- 
ysis of outcomes. The overall response to itracona- 
zole treatment is presented in Table II and re- 
sponses in each of the four different categories of 
disease in Table III. 
OVERALL RESPONSE TO ITRACONAZOLE: There 
were 25 responders and 5 nonresponders to the 30 
courses of itraconazole. All nonresponders received 
at least 200 mg daily, and one received 600 mg daily, 
over durations ranging from 6 to 18 months. Of the 
25 responders, 7 relapsed 1 to 7 months after treat- 
ment durations ranging from 6 to 18 months. Three 
of these seven responders who relapsed were treat- 
ed with a second course of itraconazole. One patient 
again responded to a 6-month course of itraconazole 
but experienced a second relapse (included twice in 
the 25 responders and twice in the 7 relapses). The 2 
other patients appear to be responding to their sec- 
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TABLE Ill 
Outcome of Treatment With ltraconazole by Disease Category 
ITZ Dose ITZ Duration 
Type of No. of (mgldl (mo) 




Remain on ITZ 1 300 WA 7.5t N/A 
Relapsed 
: 
200 WA 5.5 5-6 
Free of disease 228 100-400 6.3 3-12 
Systemic unifocal- 
pulmonary 
Nonresponder ; 300 N/A 9 N/A 
Responder 





Relapsed 400 18 !::i 
Free of disease 1 200 N/A 12 N/A 
Systemic unifocal- 
articulariosseous 
Nonresponder 400 200-400 16 12-18 
Responder 1; 
Remain on ITZ 
i 
400 N/A 6 N/A 
Relapse 350 200-400 5.8 5-6 
Lost to F/U 1 400 N/A 10 N/A 
Free of disease 4 245 200-300 7.8 6-12 
Systemic multifocal 
Nonresponder 1 400 N/A 6 N/A 
Responder 
Free of disease ; 400 N/A 11 7-15 
_.. 
: = Itraconazole; t/U = tallow-up; N/A = not applicable. 
ond course of treatment (each included twice in the 
25 responders and once in the 7 relapses). One re- 
sponder completing 10 months of treatment with 
itraconazole was lost to follow-up. Of the remaining 
17 responders, 3 remain on treatment (including 
the 2 treated previously with itraconazole but re- 
lapsing), and 14 remain free of disease. Of these 14 
responders who remain free of disease, doses ranged 
from 100 to 300 mg daily (mean: 250 mg), and fol- 
low-up duration ranged from 6 to 42 months (mean: 
17.6 months). The other responding patient, still 
remaining on his initial treatment course, has re- 
solved lesions on itraconazole. 
RESPONSEOFLYMPHOCUTANEOUSSPOROTRICHO- 
SIS TO ITRACONAZOLE: Of the 10 courses of treat- 
ment in the 9 patients with lymphocutaneous spo- 
rotrichosis, all patients were responders, although 1 
patient relapsed after both courses of itraconazole 
(counted twice as a responder who relapsed). One 
patient remains on his initial course of itraconazole 
(7.5 months) with resolution of lesions that had 
failed to respond to 5 months of treatment with 
SSKI. The duration of follow-up in the seven re- 
sponders who remained free of disease ranged from 
6 to 42 months (mean: 17.4 months). 
RESPONSE OF PULMONARY SPOROTRICHOSIS TO 
ITRACONAZOLE: Two patients with unifocal pulmo- 
nary sporotrichosis had failed prior treatment. One 
patient failed to respond to itraconazole at a dose of 
300 mg daily for 9 months. The other patient re- 
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ceived two courses of itraconazole. Despite resolu- 
tion of symptoms and improvement in radiographic 
abnormalities, this patient relapsed after his initial 
l&month course of itraconazole at 400 mg daily. 
Symptoms have improved during the second course 
at the same dose of itraconazole. The patient con- 
tinues on this treatment after 18 months and is 
considered a responder. However, sputum cultures 
still yielded S. schenckii after 12 months. The third 
patient with pulmonary sporotrichosis received 
11.5 months of itraconazole (maximum dose of 200 
mg daily) and remains free of disease 40 months 
after discontinuation. 
RESPONSE OF ARTICULAR/OSSEOUS SPOROTRI- 
CHOSIS TO ITRACONAZOLE: Twelve of the 15 pa- 
tients with articular/osseous sporotrichosis had un- 
ifocal disease. Of the 13 courses of treatment in 
those with unifocal disease, 10 were responders, and 
3 were nonresponders. Four responders relapsed 1 
to 6 months after itraconazole courses of only 5 or 6 
months at 200 to 400 mg daily. One of these patients 
continues on a second course of itraconazole at 400 
mg daily and is considered a responder at 6 months 
(included twice as a responder but only once as a 
relapse). One patient treated for 10 months was 
considered a responder but was lost to follow-up. 
The other four responders remain free of disease 
with follow-up durations of 12 to 18 months (mean: 
16.5 months). These four patients received itracon- 
azole doses of 200 to 300 mg daily over durations 
ranging from 6 to 12 months (mean: 7.8 months). Of 
the three patients with multifocal disease, one was a 
nonresponder, and two remain free of disease 6.5 
and 18 months after treatment ended. 
RESPONSE TO ITRACONAZOLE IN PATIENTS WITH 
UNDERLYING ALCOHOLISM AND DIABETES MELLI- 
TUS: Among the seven patients with underlying al- 
coholism, there were five responders and two nonre- 
sponders. Of the five responders, one was lost to 
follow-up, and four remained free of disease, only 
one of whom had lymphocutaneous sporotrichosis. 
Among the eight patients with underlying diabetes 
mellitus, there were seven responders and one non- 
responder. Of the seven responders, three relapsed, 
and four remained free of disease, only one of whom 
had lymphocutaneous sporotrichosis. 
Adverse Effects 
Twelve patients experienced adverse effects pos- 
sibly related to itraconazole treatment. Four pa- 
tients experienced nausea, and one also had vomit- 
ing. One of these patients also had malaise, 
arthralgias, and mood disturbances during the 
treatment course, but the relationship of these to 
itraconazole was unclear. Doses in these four pa- 
tients were 100 to 400 mg daily. One patient experi- 
enced a rise in serum transaminase levels to twice 
normal limits. Itraconazole treatment was held for 2 
weeks in this patient and then resumed without 
additional adverse effects. One patient experienced 
an elevation in the serum bilirubin concentration to 
2.4 mg/dL 1 month after itraconazole doses were 
raised to 600 mg daily, which resolved upon discon- 
tinuation of itraconazole. One patient experienced 
transient nervousness. 
Two patients experienced the onset of mild hyperten- 
sion during treatment with itraconazole. Both were re- 
ceiving doses of 400 mg daily. One also experienced 
peripheral edema coincident with hypertension. One 
other patient also developed peripheral edema during 
treatment. Due to underlying coronary artery disease 
and chronic renal failure in this patient, the relationship 
to itraconazole was uncertain. 
Two patients experienced possible adverse drug 
interactions while receiving itraconazole therapy. 
One patient receiving concurrent warfarin therapy 
experienced an increase in the prothrombin time. 
Another patient experienced a rise in serum digoxin 
levels requiring dosage reduction of digoxin. 
COMMENTS 
The male predominance in this series, as well as 
in most other series of sporotrichosis, is attributed 
to outdoor occupations and hobbies [2,5,6,23]. A 
higher prevalence in women has been reported from 
Japan [24]. Only three of our patients had infection 
readily attributed to hobbies or outdoor occupa- 
tional exposure. There appears to be no racial pre- 
dilection; whites represent the majority of patients 
in the current series and other reports [5]. However, 
five of the six nonwhite patients in the current se- 
ries had systemic disease. The possible influence of 
race on the presentation and course of sporotricho- 
sis deserves further study. 
Alcoholism has been recognized as a prominent 
risk factor in systemic sporotrichosis [2,4-6,8]. Of 
seven patients with alcoholism, five had articu- 
lar/osseous sporotrichosis. Other diseases reported 
as potential risk factors and noted in our patients 
include diabetes mellitus and COPD; eight of nine 
patients with these diseases had systemic sporotri- 
chosis. Immunosuppressive conditions, such as cor- 
ticosteroid therapy, hematologic malignancy, 
transplantation, or human immunodeficiency virus 
infection, were not seen in our patients [5-8,24-261. 
Pulmonary sporotrichosis, once thought rare, has 
been increasingly recognized [2]. Cavitary upper 
lobe lesions are characteristic of unifocal systemic 
pulmonary sporotrichosis [2-5,271. This presenta- 
tion is easily confused with reactivation pulmonary 
tuberculosis. In contrast, pulmonary involvement 
in multifocal systemic disease, noted in approxi- 
mately 20% of patients, is characterized by linear 
and nodular infiltrates [2]. 
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Articular/osseous sporotrichosis is most often 
thought to follow hematogenous dissemination 
rather than inoculation with contiguous invasion 
[2,6,8,9,23]. Typical radiographic abnormalities in- 
clude erosions of the articular surfaces with lytic 
lesions of the surrounding bone [2,8,23]. The lower 
extremity is most frequently involved [6,23]. Inter- 
estingly, all of our patients with unifocal articu- 
lar/osseous sporotrichosis of the upper extremity 
had involvement on the right. Assuming hematoge- 
nous dissemination as the underlying pathogenesis, 
one would expect an equal distribution between the 
right and left upper extremities as well as involve- 
ment of the axial skeleton. Thus, there may be a role 
for local inoculation in the pathogenesis of some 
cases of articular/osseous sporotrichosis. 
Cutaneous inoculation sporotrichosis usually re- 
sponds to SSKI [4,5,13,18,20]. Although SSKI is 
inexpensive, it is frequently not well tolerated [18]. 
Allergic reactions and gastrointestinal intolerance 
are common [4,18]. Systemic sporotrichosis is usu- 
ally resistant to treatment with iodides and requires 
therapy with amphotericin B [2,4-6,8,10,20,23]. 
However, some patients fail to respond, and re- 
lapses do occur [4,5,7,10]. In addition, amphotericin 
B has significant toxicity and inherent difficulties 
associated with intravenous administration [14]. 
Intra-articular administration of amphotericin B 
has been successful in a few patients with articular 
involvement [28]. Surgical intervention combined 
with iodides or amphotericin B increases the effica- 
cy of treatment of pulmonary and articular/osseous 
sporotrichosis [2,4,5,8,10,23]. 
Successful treatment with intravenous miconazole in 
pulmonary sporotrichosis resistant to amphotericin B 
has been reported [29]. However, miconazole has failed 
in other cases and also has associated toxicities 
[4,5,14,29]. Treatment with ketoconazole has been asso- 
ciated with variable results. Although an initial response 
may occur, relapses are not infrequent [4,5,27,30-34]. 
One series reported a better response rate when doses of 
400 to 800 mg daily were used [31]. Many of these 
patients had concurrent surgical debridement, and the 
majority were treated for more than 1 year [31]. The 
authors suggested that the high proportion of sustained 
remissions they observed may have related to the longer 
duration of treatment [31]. Unfortunately, at these 
higher doses, a greater incidence and severity of adverse 
effects, including gastrointestinal and endocrine effects, 
are noted [14,30,35,36]. 
The primary mechanism of the action of itracon- 
azole, as with other azoles, is inhibition of ergosterol 
biosynthesis. In vitro studies have demonstrated 
the minimal inhibitory concentration (MIC) of itra- 
conazole for S. schenckii (yeast phase) to be from 
0.1 to 12.5 mg/L, similar to the MIC of 0.1 to 10 
mg/L for ketoconazole [17,18,21,31]. 
Efficacy with itraconazole, at 100 mg daily, was 
demonstrated in the treatment of lymphocutan- 
eous sporotrichosis in a series from South America. 
Of 17 patients treated for a mean duration of 130 
days, 14 remained free of relapse with an average 
follow-up of 115 days [18]. A report of five patients 
from Mexico also supported the efficacy of itracon- 
azole at doses of 100 to 200 mg daily [20]. In patients 
with lymphocutaneous sporotrichosis in this series, 
we found a similar response rate. All nine patients 
responded, one remains on treatment, and seven 
remain free of disease after discontinuation of itra- 
conazole over a mean follow-up duration of 17 
months. Relapse occurred in only one patient, to 
two separate courses. 
The treatment of pulmonary sporotrichosis is 
problematic [4,5,10,27]. Cure rates of unifocal pul- 
monary sporotrichosis treated with amphotericin B 
are less than 50% [4,5,10]. Cure rates as high as 70% 
to 80% have been achieved with a combination of 
surgical resection and amphotericin B or -SSKI. 
However, resection is not always feasible, especially 
in patients with underlying COPD [4,5,10]. Out- 
comes with miconazole and ketoconazole have 
failed to document their efficacy [5,27,29,30]. With 
only three patients with pulmonary sporotrichosis, 
it is difficult to compare our treatment outcomes 
with itraconazole to those of other therapies, but it 
appears to be no better than noted previously. 
Articular/osseous sporotrichosis has also been 
very difficult to treat. SSKI is ineffective 
[1,2,6,8,10,21]. At least 30% to 40% of patients treat- 
ed with amphotericin B fail therapy or relapse 
[10,23,28]. In successful cases, a total dose of 1 to 5 g 
of amphotericin B has been required [1,2,6,8,10,23]. 
Treatment outcomes with ketoconazole, for articu- 
lar/osseous sporotrichosis, have been variable 
[30-331. Some authors have suggested that higher 
doses and longer durations may result in more fa- 
vorable outcomes and sustained remissions [31,33]. 
In the 15 patients with articular/osseous sporotri- 
chosis in the current series, itraconazole treatment 
outcomes were comparable to those reported with 
other therapies. Eleven of the 15 patients were con- 
sidered responders. However, 4 of these 11 relapsed 
1 to 6 months later, and no follow-up is available in 
1. All four patients relapsing had received only 5 to 
6 months of treatment. The other six patients, in- 
cluding two with multifocal involvement, remain 
free of disease over a mean follow-up duration of 15 
months. 
The results in the current series of patients with 
sporotrichosis support the efficacy of itraconazole. 
Favorable results were obtained in both cutaneous 
inoculation and systemic sporotrichosis. In the 18 
patients with systemic sporotrichosis in this series, 
the treatment outcomes with itraconazole are com- 
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parable to results with amphotericin B and keto- 
conazole. Unfortunately, no pill counts or measure- 
ment of serum levels were done to assess 
itraconazole compliance. 
Itraconazole therapy appears to have less toxicity 
than either ketoconazole or amphotericin B. The 
occurrence of hypertension, which was seen in two 
patients treated with 400 mg daily, has been noted 
previously [16]. This side effect appears to respond 
to conservative medical management and should 
not interfere with therapy [16]. Itraconazole repre- 
sents a reasonable alternative to amphotericin B 
and may be more efficacious than ketoconazole in 
the treatment of systemic sporotrichosis. In the 
treatment of lymphocutaneous sporotrichosis, itra- 
conazole represents a reasonable alternative to 
SSKI. It may be better tolerated than SSKI, and it 
may offer a less toxic alternative over either keto- 
conazole or amphotericin B. Itraconazole should be 
a very useful addition to the antifungal armamen- 
tarium for treatment of sporotrichosis. 
APPENDIX 
Other Members of the NlAlD Mycoses Study Group 
John Bennett, M.D., National Institute of Aller- 
gy and Infectious Diseases, Bethesda, MD; Robert 
W. Bradsher, M.D., University of Arkansas for 
Medical Sciences, Little Rock, AR; Stanley W. 
Chapman, M.D., University of Mississippi Medical 
Center, Jackson, MS; John F. Fisher, M.D., Medical 
College of Georgia, Augusta, GA; Thomas M. Ker- 
kering, M.D., Medical College of Virginia, Rich- 
mond, VA; Gerald Medoff, M.D., Washington Uni- 
versity School of Medicine, St. Louis, MO; John R. 
Perfect, M.D., Duke University Medical Center, 
Durham, NC; George A. Pankey, M.D., Ochsner 
Clinic, New Orleans, LA; J.H. Rex, M.D., National 
Institute of Allergy and Infectious Diseases, Be- 
thesda, MD; Michael S, Saag, M.D., University of 
Alabama at Birmingham, Birmingham, AL. 
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